Table 1.

Experimental protocol groups.

SAL	Received inhalations with sterile saline solution
SAL-RHO inhibitor	Received inhalations with sterile saline and 1 h before the challenge they received treatment with Rho-kinase inhibitor (10 mg/kg)
SAL-anti-IL17	Received inhalations with sterile saline and 1 h before the challenge they received treatment with anti-IL17 (7.5 μg/application)
SAL-RHO inhibitor-anti-IL17	Received inhalations with sterile saline and 1 h before the challenge they received treatment with Rho-kinase inhibitor (10 mg/kg) associated with treatment with an anti-IL17 (7.5 μg/application)
OVA	Received inhalations of a solution of ovalbumin
OVA-RHO inhibitor	Received inhalations of a solution of ovalbumin and 1 h before the challenge they received treatment with Rho-kinase inhibitor (10 mg/kg)
OVA-anti-IL17	Received inhalation of OVA solution and 1 h before the challenge they received treatment with an anti-IL17 (7.5 μg/application)
OVA-RHO inhibitor-anti-IL17	Received inhalations of a solution of ovalbumin and 1 h before the challenge they received treatment with Rho-kinase inhibitor (10 mg/kg) associated with treatment with an anti-IL17 (7.5 μg/application)

IL, interleukin.